Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone i and posterior zone II retinopathy of prematurity

British Journal of Ophthalmology

Volumn 98, Issue 4, 2014, Pages 507-512

  Tahija, Sjakon G ^a   Hersetyati, Rini ^a   Lam, Geoffrey C ^b   Kusaka, Shunji ^c   McMenamin, Paul G ^d  

^a Klinik Mata Nusantara   (Indonesia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c OSAKA GENERAL MEDICAL CENTER   (Japan)

^d MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; FLUORESCEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; DRUG EFFICACY; DRUG RESPONSE; EYE PHOTOGRAPHY; GROWTH INHIBITION; HUMAN; NEWBORN; OPHTHALMOSCOPY; PRIORITY JOURNAL; RETINA BLOOD VESSEL; RETINA FLUORESCEIN ANGIOGRAPHY; RETROLENTAL FIBROPLASIA; RETROSPECTIVE STUDY; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; CAPILLARY PERMEABILITY; CASE REPORT; CLASSIFICATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; GESTATIONAL AGE; INFANT; INTRAVITREAL DRUG ADMINISTRATION; LOW BIRTH WEIGHT; MALE; METABOLISM; PATHOLOGY; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CAPILLARY PERMEABILITY; FEMALE; FLUORESCEIN; FLUORESCEIN ANGIOGRAPHY; GESTATIONAL AGE; HUMANS; INFANT; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; INTRAVITREAL INJECTIONS; MALE; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; RETINOPATHY OF PREMATURITY; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84896548614     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2013-304109     Document Type: Article

References (25)

1. Zin A, Gole GA. Retinopathy of prematurity-incidence today. Clin Perinatol 2013;40:185-200.
2. Katz X, Kychenthal A, Dorta P. Zone I retinopathy of prematurity. J Aapos 2000;4:373-6.
3. Drenser KA, Trese MT, Capone A Jr. Aggressive posterior retinopathy of prematurity. Retina 2010;30(4 Suppl):S37-40.
4. Good WV, Hardy RJ. The multicenter study of Early Treatment for Retinopathy of Prematurity (ETROP). Ophthalmology 2001;108:1013-14.
5. Azuma N, Ishikawa K, Hama Y, et al. Early vitreous surgery for aggressive posterior retinopathy of prematurity. Am J Ophthalmol 2006;142:636-43.
6. Vinekar A, Trese MT, Capone A Jr. Evolution of retinal detachment in posterior retinopathy of prematurity: impact on treatment approach. Am J Ophthalmol 2008;145:548-55.
7. Azad R, Chandra P. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol 2007;55:319; author reply 20.
8. Chung EJ, Kim JH, Ahn HS, et al. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2007;245:1727-30.
9. Lalwani GA, Berrocal AM, Murray TG, et al. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 2008;28:S13-18.
10. Mintz-Hittner HA, Kuffel RR Jr. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 2008;28:831-8.
11. Quiroz-Mercado H, Martinez Castellanos M, Hernandez-Rojas M, et al. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 2008;28:S19-25.
12. Travassos A, Teixeira S, Ferreira P, et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging 2007;38:233-7.
13. Kusaka S, Shima C, Wada K, et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol 2008;92:1450-5.
14. Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011;364:603-15.
15. Blair MP, Shapiro MJ, Hartnett ME. Fluorescein angiography to estimate normal peripheral retinal nonperfusion in children. J Aapos 2012;16:234-7.
16. Ng EY, Lanigan B, OKeefe M. Fundus fluorescein angiography in the screening for and management of retinopathy of prematurity. J Pediatr Ophthalmol Strabismus 2006;43:85-90.
17. Wagner RS. Fundus fluorescein angiography in retinopathy of prematurity. J Pediatr Ophthalmol Strabismus 2006;43:78.
18. Lepore D, Molle F, Pagliara MM, et al. Atlas of fluorescein angiographic findings in eyes undergoing laser for retinopathy of prematurity. Ophthalmology 2011;118:168-75.
19. Velia P, Antonio B, Patrizia P, et al. Fluorescein angiography and retinal vascular development in premature infants. J Matern Fetal Neonatal Med 2012;25(Suppl 3):53-6.
20. Dorta P, Kychenthal A. Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin). Retina 2010;30(4 Suppl):S24-31.
21. Harder BC, von Baltz S, Jonas JB, et al. Intravitreal bevacizumab for retinopathy of prematurity. J Ocul Pharmacol Ther 2011;27:623-7.
22. Carden SM, Luu LN, Nguyen TX, et al. Retinopathy of prematurity: postmenstrual age at threshold in a transitional economy is similar to that in developed countries. Clin Experiment Ophthalmol 2008;36:159-61.
23. Gu MH, Jin J, Yuan TM, et al. Risk factors and outcomes for retinopathy of prematurity in neonatal infants with a birth weight of 1,501-2,000 g in a Chinese Neonatal Unit. Med Princ Pract 2011;20:244-7.
24. Kaiser RS, Fenton GL, Tasman W, et al. Adult retinopathy of prematurity: retinal complications from cataract surgery. Am J Ophthalmol 2008;145:729-35.
25. Kaiser RS, Trese MT, Williams GA, et al. Adult retinopathy of prematurity: outcomes of rhegmatogenous retinal detachments and retinal tears. Ophthalmology 2001;108:1647-53.